HCA Healthcare stock (US40412C1018): Shares ease after prior gains as investors focus on valuation metrics

HCA Healthcare shares on the NYSE edged lower in the latest session after a strong run in 2026, with investors reassessing valuation metrics such as earnings multiples and cash generation for the US hospital operator.

HCA Healthcare shares on the New York Stock Exchange traded around the mid-USD 380s at the close on 05/28/2026 after a period of solid gains earlier in 2026, leaving the stock modestly lower on the day as investors reassessed the valuation of the United States-based hospital operator, according to MarketBeat data as of 05/28/2026.

The stock price movement comes against the backdrop of a roughly 4.3% year-on-year revenue increase reported in the most recent quarterly update, which underpins the company’s financial profile but also raises questions about how much of that growth is already reflected in current earnings multiples, according to a summary of the latest figures on MarketBeat as of 05/28/2026.

HCA Healthcare is part of the US large-cap healthcare universe and trades on the NYSE under the ticker HCA, which anchors the stock firmly in the United States market where it is followed by both domestic and international investors monitoring health systems and hospital operators.

The stock’s valuation is a key focus at the end of May 2026 because the share price around USD 384.01 at the close on 05/28/2026 compares with consensus analyst expectations that still imply upside over a 12-month horizon, based on data compiled by MarketBeat as of 05/28/2026.

The price of approximately USD 384 per share as of 05/28/2026 represents the reference point for several popular valuation ratios and frames how investors evaluate the balance between HCA Healthcare’s earnings power, leverage and free cash flow profile on the US market as of late May 2026.

The stock traded at 384.01 USD on 05/28/2026 on the New York Stock Exchange, according to a snapshot from MarketBeat as of 05/28/2026.

In Germany, the stock is also available to local investors via off-exchange trading systems such as Tradegate, where it can be followed in euros as an additional reference, although the primary listing and core liquidity remain concentrated on the NYSE in the United States.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: HCA Healthcare
• Sector/industry: Hospital and healthcare services
• Headquarters/country: Nashville, United States
• Core markets: Acute-care and specialty hospitals in the United States
• Key revenue drivers: Inpatient and outpatient services, surgical procedures, emergency care and related healthcare services across its US hospital network
• Home exchange/listing venue: New York Stock Exchange (HCA)
• Trading currency: USD

HCA Healthcare: core business model

HCA Healthcare operates a broad network of acute-care hospitals and outpatient facilities across the United States, generating most of its revenue from a mix of inpatient admissions, outpatient treatments, surgical procedures and emergency services reimbursed by private insurers, government programs and self-pay patients.

Valuation metrics and multiples for HCA Healthcare

Because HCA Healthcare remains a core US hospital operator with stable demand dynamics, its valuation framework is closely tied to earnings-based and cash flow-based metrics such as the price-earnings ratio and enterprise-value-to-EBITDA, which investors use to benchmark the stock against both its own history and listed US hospital peers, based on data collated on platforms such as MarketBeat and other market data providers as of 05/28/2026.

MarketBeat reports that the consensus 12-month price target for HCA Healthcare stands at approximately USD 515.77 as of 05/28/2026, based on the most recent research views of 24 Wall Street analysts, with a high target of USD 635.00 and a low target of USD 425.00, which together frame the range of assumptions analysts are using for earnings growth, margins and capital allocation when calibrating their valuation models.

Conclusion

With HCA Healthcare’s share price consolidating around the mid-USD 380s on the NYSE after earlier gains in 2026, investors in the United States are refocusing on how current levels line up with the company’s earnings power and hospital network scale.

The consensus analyst price target near USD 515.77 as of 05/28/2026 suggests that research houses still model further upside relative to the latest close, but the breadth of estimates between USD 425.00 and USD 635.00 highlights the sensitivity of valuation outcomes to assumptions about margins, capital spending and reimbursement trends in the US healthcare system.

For market participants tracking the stock, the key questions now center on whether HCA Healthcare can continue to translate its US hospital footprint and revenue growth into sustained earnings expansion that would support the current valuation metrics implied by both the share price and analyst models.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.